Introduction {#S1}
============

*Collision tumor* is a well documented but uncommon phenomenon characterized by coexistence of two completely distinct and independent tumors at the same site. The two morphologically separate tumors are sharply demarcated from each other in the same site. This entity is distinct from neoplasms demonstrating heterologous or mixed elements.

Various collision tumors have been documented in different organs of the body. Previously documented cases of collision tumor in the gastrointestinal tract include gastric collision tumor such as an unusual combination of adenocarcinoma and immature neuroepitheliomatous teratoma^[@R1]^ in the stomach, collision of Epstein-Barr virus-associated gastric carcinoma and primary gastric extranodal marginal zone lymphoma,^[@R2]^ gastrointestinal stromal tumor and gastric adenocarcinoma collision tumors,^[@R3]^ gastric collision tumor of large cell neuroendocrine carcinoma and adenocarcinoma,^[@R4]^ and mixed adenocarcinoma-carcinoid in the appendix;^[@R5]^ a rare combination of an adenocarcinoma and small cell neuroendocrine tumor in the ileum;^[@R6]^ adenoma-carcinoid tumors of the colon;^[@R7]^ and collision tumor of the ampulla of Vater with carcinoid and adenocarcinoma components.^[@R8],[@R9]^

Duodenal adenocarcinoma in a site other than around the ampulla of Vater is uncommon, and the presence of a collision tumor in this location is rather rare. No collision tumor from the duodenum other than the ampulla of Vater has been reported to date. Our case involves a patient with distinct adenocarcinoma and neuroendocrine carcinoma located in the third portion of the duodenum 4.5 cm distal to the ampulla of Vater. Grossly, the duodenal mass was a 3 cm-sized ulcerative fungating lesion. Microscopically, two separated tumors were recognized. The lineages of both tumors were confirmed by immunohistochemistry. Such collision tumor is very rare and may thus provide diagnostic challenges. Clinicians and pathologists should be aware of such an association in order to make a correct diagnosis and initiate the proper treatment.

Case Report {#S2}
===========

A previously healthy 52 year-old man with a family history of pancreatic cancer developed progressive daily vomiting over six months prior to presentation. He had a normal appetite and could tolerate a regular diet, but reported increasing postprandial vomiting. He has also noted a 125-lb weight loss over the past 9 months. On endoscopy he was found to have a near-complete obstructing mass at the third portion of the duodenum, but biopsies failed to confirm a neoplastic condition. Computed tomography scan demonstrated duodenal obstruction and abnormal para-duodenal lymph nodes ([Figure 1](#F1){ref-type="fig"}A). Intraoperatively the findings were consistent with a mass of approximately 3 cm in size, but it was somewhat unclear whether this was an extra-duodenal mass involving the duodenum secondarily, or a duodenal mass involving the uncinate process of the pancreas. The mass was completely resected via pylorus-sparing pancreatoduodenectomy. On pathological examination, this 3 cm ulcerated tumor ([Figure 1](#F1){ref-type="fig"}B) was located in the third portion of duodenum 4.5 cm distal to ampulla of Vater, deeper located to it is an independent 1 cm distinctive nodule ([Figure 1](#F1){ref-type="fig"}C).

Figure 1A) Computed tomography scan showing the level of duodenal obstruction, and an abnormal paraduodenal lymph node; B) Macroscopic findings: an ulcerated tumor (3.0×2.5×1.4 cm) is located in the third portion of duodenum about 4.5 cm distal from ampulla of Vater of duodenum; C) Macroscopic findings: cross-section of the ulcerated tumor (blue arrow) and in the same location deeper from the tumor above, a completely distinct and independent 1 cm tumor (black arrow) deep in subserosa.

Microscopically, the main tumor showed poorly differentiated adenocarcinoma morphology ([Figure 2](#F2){ref-type="fig"}A) that had infiltrated into subserosal adipose tissue; the other lesion in the same location located deeper from the adenocarcinoma described above showed neuroendocrine morphology, such as nests and trabeculae with variable amounts of eosinophilic cytoplasm, indicating a completely distinct and independent neuroendocrine carcinoma ([Figure 3](#F3){ref-type="fig"}A). Histologically, the pancreas was not involved with either tumor. Three positive lymph nodes were identified out of a total of forty. One of them demonstrated coexistent metastatic adenocarcinoma and neuroendocrine carcinoma ([Figure 4](#F4){ref-type="fig"}A). The immunohistochemical characteristics were analyzed to determine whether the origins of the 2 cancers were different or not. The adenocarcinoma neoplastic cells revealed expression of CK7, CK20 and Cd×2 but no expression of neuroendocrine markers such as CD56, chromogranin and synaptophysin ([Figure 2](#F2){ref-type="fig"}B, C, D). The tumor cells in the independent 1 cm tumor nodule show strong neuroendocrine marker expression including CD56, chromogranin and synaptophysin, but negativity for CK7, CK20 and Cd×2 ([Figure 3](#F3){ref-type="fig"}B,C,D). The immunostains were also done on the involved lymph node which confirmed the double metastasis ([Figure 4](#F4){ref-type="fig"}B,C). This phenomenon is very rare and can be referred to as *collision metastasis*. The other two lymph nodes were positive for neuroendocrine carcinoma. As a result, it was concluded that this was a case of collision cancer of primary duodenal adenocarcinoma and neuroendocrine carcinoma with collision metastasis into one lymph node. The patient has recovered well from his operation, and is currently symptom-free.

Figure 2Histological photomicrograph of the main tumor showing adenocarcinoma morphology (A), and immunohistochemically tumor cells with complete negativity for synaptophysin (B), but with strong cytoplasmic and membrane reactivity for CK7 (C) and nuclear stain for cdx2 (D).

Figure 3Histological photomicrograph of the independent 1 cm tumor composed of nests of small cells with uniform round nuclei. The nuclei of the neoplastic cells have classic salt and pepper chromatin (A), immunohistochemically the tumor cells are diffuse and strong positivity for synaptophysin (B), negative for CK7 (C) and cdx2 (D).

Figure 4A) Collision metastasis in a single lymph node: Black arrow points to neuroendocrine carcinoma; blue arrow marks adenocarcinoma; B) Immunohistochemical study for synaptophysin: positive for metastatic neuroendocrine tumor; negative for the adenocarcinoma metastasis; C) Immunohistochemical study for cdx2: negative for metastatic neuroendocrine, positive for the adenocarcinoma metastasis.

Discussion {#S3}
==========

Before the present case, a total of four reported cases of duodenal collision tumor were found in the MedLine-listed literature. Our literature review has purposely been limited to collision tumors of duodenum excluding those from colorectal, gastric, appendiceal and other parts of the gastrointestinal tracts. The clinicopathologic features of these cases are summarized in [Table 1](#T1){ref-type="table"}.^[@R8]--[@R11]^

Table 1Clinicopathologic features of current and previous reported collision tumor in duodenum.Author and yearAge/SexLocation/sizeHistopathologyMarco *et al.* 200764/MDuodenal wall and head of pancreas^[@R8]^Duodenal carcinoid (1 cm) and\
adenocarcinoma of head of pancreas (3 cm)Williams *et al.* 199758/MAmpulla of Vater^[@R9]^Carcinoid tumor (0.6 cm) and adenocarcinoma (0.6 cm)Varikatt *et al.* 200637/FAmpulla of Vater^[@R10]^Somatostatinoma (3.5 cm) and neurofibroma (2.0 cm)Hirono *et al.* 200875/MAmpulla of Vater and proximal bile duct^[@R11]^The ampulla of Vater shows a papillo-tubular carcinoma with a\
marked prodection of mucin suggesting an intestinal type of ampullary\
adenocarcinoma, and well differentiated carcinoma of bile ductPresent case52/MThird portion of duodenumPrimary adenocarcinoma (3.0 cm) and neuroendocrine carcinoma\
of duodenum (1 cm)

Conventional explorations usually do not confirm the coexistence of both tumors, as these findings are frequently made incidentally during histopathologic examination of the specimen. Given their extreme rarity in this location and the nature of collision tumors, it is of certain diagnostic benefit to extensively examine and section the tumor for histologic evaluation, and distinguish collision tumor from the more commonly encountered neoplasms demonstrating heterologous differentiated elements or mixed elements.

Indeed, this case could easily have been mis-considered as an *adenocarcinoma with neuroendocrine features* given the rarity of collision tumors in this location, and one may even completely miss the concurrent distinct and independent neuroendocrine tumor component, especially if only a limited examination and sectioning of the tumor are performed for histologic evaluation.

Two main features that are important in the diagnosis of collision tumor rather than neoplasms demonstrating mixed elements include: i) two distinctive and spatially independent tumor components macroscopically in the same location, and ii) demarcated morphology and immuno-expression patterns among the two tumors microscopically. Morphological and immunohistochemical examinations will show that the two components have a clear-cut distinction, and they have no intervening intermediate cell population.

Clinical implications of this condition and the mechanism responsible for the tumor formation of such an unusual constellation remain unclear. Mutual factors of carcinogenic initiation or progression for either tumor component can be speculated upon, but are unknown. In addition, the collision tumor encountered provided us with the curiosity finding of simultaneous and apparently independent lymphatic metastatic progression mechanisms, too. Since this is apparently the first such case of collision tumor arising in the third portion of duodenum, further study of additional cases and additional long-term follow-up will likely be necessary to better understand the clinical behavior of such tumors occurring in this unusual location. We suspect that the recurrence risk of the tumor encountered will most likely be primarily influenced by the biologic behavior of the more aggressive component, *i.e.* the duodenal adenocarcinoma. Nevertheless, having identified two separate invasive neoplastic processes will have an influence on postoperative treatment and follow-up decisions.
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